All In Biotech

Drug Trial Radar · NCT07421700

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Mar 11, 2026

Primary completion

Dec 28, 2027

Study completion Sep 25, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Astellas Pharma Inc
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone. * Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin. Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable. Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer. If the cancer gets worse but the treatment is still helping and side effects are manageable, participants may be allowed to continue treatment with their doctor's and the sponsor's agreement.

Conditions

  • Urothelial Cancer
  • Advanced/Metastatic Urothelial Cancer
  • Urothelial Carcinoma

Interventions

  • PF-08634404Biological

    Concentrate for solution for Infusion.

  • Enfortumab VedotinBiological

    Powder for concentrate for solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) by investigatorTime frame: Up to approximately 3 years
  2. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through 90 days after the last study intervention; Up to approximately 3 years
  3. Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort BTime frame: Through 90 days after the last study intervention; Up to approximately 3 years

Locations

184 sites in 6 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Springdale, Arkansas · Recruiting

  • UCLA Hematology/Oncology - Alhambra

    Alhambra, California · Recruiting

  • UCLA Hematology/Oncology - Atascadero

    Atascadero, California · Recruiting

  • UCLA Hematology/Oncology - Beverly Hills

    Beverly Hills, California · Recruiting

  • UCLA Hematology/Oncology - Burbank

    Burbank, California · Recruiting

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Recruiting

  • City of Hope Investigational Drug Services (IDS)

    Duarte, California · Recruiting

  • UC San Diego Medical Center - Encinitas

    Encinitas, California · Recruiting

  • UCLA Hematology/Oncology - Encino

    Encino, California · Recruiting

  • UCLA Hematology/Oncology - Irvine

    Irvine, California · Recruiting

  • Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UCI Health - Irvine Infusion Pharmacy ACC

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope Investigational Drug Service (IDS)

    Irvine, California · Recruiting

  • UC San Diego Koman Family Outpatient Pavilion

    La Jolla, California · Recruiting

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UC San Diego Shiley Eye Institute

    La Jolla, California · Recruiting

  • UC San Diego Sulpizio Cardiovascular Center

    La Jolla, California · Recruiting

  • Viterbi Family Department of Ophthalmology

    La Jolla, California · Recruiting

  • UCLA Hematology Oncology- Laguna Hills

    Laguna Hills, California · Recruiting

  • City of Hope-Long Beach (ELM)

    Long Beach, California · Recruiting

  • START Los Angeles, LLC

    Los Angeles, California · Recruiting

  • Los Angeles Cancer Network - Century City

    Los Angeles, California · Recruiting

  • (IRB# 26-0433) Ronald Reagan UCLA Medical Center, Drug Information Center

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology - Marina del Rey

    Marina del Rey, California · Recruiting

  • UC Irvine Health

    Orange, California · Recruiting

  • UCLA Hematology/Oncology - Pasadena

    Pasadena, California · Recruiting

  • UCLA Hematology Oncology - Porter Ranch

    Porter Ranch, California · Recruiting

  • UC San Diego Medical Center - Bankers Hill

    San Diego, California · Recruiting

  • UC San Diego McGrath Outpatient Pavilion - Hillcrest

    San Diego, California · Recruiting

  • UC San Diego Medical Center- Hillcrest

    San Diego, California · Recruiting

  • UC San Diego Medical Center - Rancho Bernardo

    San Diego, California · Recruiting

  • UCLA Hematology/Oncology - San Luis Obispo

    San Luis Obispo, California · Recruiting

  • UCLA Hematology/Oncology- Santa Barbara

    Santa Barbara, California · Recruiting

  • UCLA Hematology/Oncology- Santa Monica

    Santa Monica, California · Recruiting

  • UCLA Hematology/Oncology - Torrance

    Torrance, California · Recruiting

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.